June 5 (Reuters) – Johnson & Johnson’s therapy for
advanced multiple myeloma sharply reduced the risk of disease
progression when taken with two standard treatments for the
blood cancer, according to…
The post J&J myeloma drug, in combo regimen, delays worsening of the disease appeared first on NASDAQ.